AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06430567 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction (10% AOP compression) in the rehabilitation phase after Latarjet surgery for chronic shoulder instability
Description: Participants undergoing shoulder instability surgery (Latarjet procedure) by a single surgeon will receive standard physiotherapy (2 sessions per week) before being randomized into 3 groups at their 6th postoperative week check-up:~Group 2) BFR Group with 10% AOP compression~Group 2 will perform a 30-minute strengthening session twice weekly during postoperative weeks 7 to 14. They will do 4 exercises, completing 4 sets with 30-second rest intervals and 1 minute between exercises, following 15-15-15-15 at 70% 1RM~Exercise :~External rotation with pulley/band Internal rotation with pulley/band Frontal elevation with hyperpronation Diagonal abduction-external rotation with pulley/band~BFR training will use the MadUp© system, placing the band proximally on the operated arm, with a central unit continuously monitoring and calibrating arm pressure.
Study NCT06230926 — intervention group
Intervention type: OTHER
Intervention: Validity, Reliability and Adaptation
Description: The Hoehn \& Yahr Scale (HDS) and the Unified Parkinson's Disease Rating Scale (UPDRS) will be used for the clinical evaluation and disease staging of the individuals included in the study. In addition to the PDQoL-7 questionnaire, the 'Short Form-36' and 'Parkinson's Disease Questionnaire-39' questionnaires will be administered to patients to assess concurrent validity. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants. To determine the test-retest reliability, the PDQoL7 questionnaire will be administered again to the same patients after 2 weeks.
Study NCT06231888 — intervention group
Intervention type: DEVICE
Intervention: Aligner
Description: Orthodontic alginer
Study NCT05587530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment engagement and retention intervention for suicidal clients
Description: The manualized behavioral intervention for treatment engagement and retention of suicidal clients will be based on client and staff stakeholder preferences, informed by data from qualitative participatory interviews and secondary data analysis of administrative databases (conducted in phase 1). In addition to factors identified by stakeholders, if deemed feasible and acceptable during phase 1, the intervention will include structured phone outreach, shared decision-making, and peer support.
Study NCT05586347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: Nicardipine 0.2-0.5μg/(kg·min) was infused at the beginning of CPB.
Study NCT05586347 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: It has the same capacity as group N。
Study NCT04870216 — intervention group
Intervention type: OTHER
Intervention: Questionnaire regarding intimate protections habit.
Description: Questionnaire regarding intimate protections habit.
Study NCT05042219 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI and Echocardiography before treatment initiation of pulmonary disease and 3 months thereafter
Study NCT04640376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dummy treatment
Study NCT04640376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dummy treatment
Study NCT04341779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing and tenofovir adherence testing
Description: Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
Study NCT06580886 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: All patients having ultrasound with Clarius L15/L20 and GE logic E9/E10 in same visit.
Study NCT05430750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.
Study NCT05430750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.
Study NCT05430750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Ventilation will be initiated with 2% sevoflurane in all the groups
Study NCT06188364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
Study NCT06188364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion.
Study NCT04580940 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass™ Discover Digital System
Description: Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
Study NCT05490368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed mattress sensor system
Description: The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
Study NCT05611476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Muscular Therapy for low back pain
Description: Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
Study NCT06328205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.
Study NCT06328205 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.
Study NCT06328205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Nerve Block
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
Study NCT06291272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: 15 g psyllium + 15 g inulin
Study NCT06291272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Description: 15 g methylcellulose + 15 g inulin
Study NCT06291272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: 15 inulin
Study NCT06291272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 inulin
Study NCT06291272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 15 maltodextrin
Study NCT06328205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.
Study NCT06328205 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. 1 milliliter of normal saline will be used for injection.
Study NCT05131841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipterbin Combined With Vinorelbine
Description: 1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
Study NCT05131841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipterbin Combined With Vinorelbine
Description: 1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
Study NCT05629780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resuscitation fluid
Description: Cristalloid fluids given as a resuscitational intervention
Study NCT05186805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof cream, 1%
Description: Tapinarof cream, 1% applied topically once daily
Study NCT05482113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
Study NCT05482113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
Study NCT06270381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.
Study NCT06270381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
Study NCT06416774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.05mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.
Study NCT06416774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.1mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.
Study NCT06416774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.07mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.
Study NCT05403541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study NCT05403541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study NCT05403541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo SC
Description: Placebo
Study NCT05403541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC bi-weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study NCT04850300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee prosthesis with medial condylar stabilization
Description: Surgery will be done of Total knee prosthesis with medial condylar stabilization
Study NCT04850300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee prosthesis with central pivot stabilization
Description: Surgery will be done of Total knee prosthesis with central pivot stabilization
Study NCT05668754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serdexmethylphenidate
Description: Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
Study NCT05668754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate
Description: Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.
Study NCT05668754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
Study NCT06219239 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KL003 cell injection Drug Product
Description: No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
Study NCT06075758 — intervention group
Intervention type: OTHER
Intervention: ribociclib
Description: There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription.
Study NCT05046795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 mcg in 3 ML Inhalation Solution
Description: Revefenacin
Study NCT05046795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation solution QD
Description: Placebo
Study NCT03782155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine supplementation
Description: powder 14g
Study NCT03782155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB
Description: powder 3g
Study NCT03782155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: powder 17g
Study NCT06188065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood eosinophil count
Description: To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
Study NCT04290026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide versus granisetron
Description: ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
Study NCT06495736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental: ROSE technique stain
Description: The ROSE technical group uses Diff-Quick stain for diagnosis
Study NCT05913622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump
Description: An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
Study NCT05525494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Fixed R/R Messages with Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by text. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study NCT05525494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Pre-Appointment Reminder
Description: Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period.
Study NCT05525494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link
Description: Participants in this arm will receive a pre-commitment prompt message by portal in September. Tailored R/R messages will be sent monthly by portal based on time and place selected by patients (up to 3). R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study NCT05525494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Fixed R/R Messages with Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by portal. R/R message will be sent with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study NCT05525494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Pre-Appointment Reminder
Description: Participants will receive a Pre-Appointment Reminder advising them to ask their doctor for the flu vaccine at their upcoming appointment via portal when they schedule a visit during the study period.